Pharmacological Reviews最新文献

筛选
英文 中文
Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer. 异常Janus激酶信号与组蛋白去乙酰化酶家族表观遗传修饰因子串扰的药理调节治疗癌症。
IF 21.1 1区 医学
Pharmacological Reviews Pub Date : 2023-01-01 DOI: 10.1124/pharmrev.122.000612
Al-Hassan M Mustafa, Oliver H Krämer
{"title":"Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer.","authors":"Al-Hassan M Mustafa,&nbsp;Oliver H Krämer","doi":"10.1124/pharmrev.122.000612","DOIUrl":"https://doi.org/10.1124/pharmrev.122.000612","url":null,"abstract":"<p><p>Hyperactivated Janus kinase (JAK) signaling is an appreciated drug target in human cancers. Numerous mutant JAK molecules as well as inherent and acquired drug resistance mechanisms limit the efficacy of JAK inhibitors (JAKi). There is accumulating evidence that epigenetic mechanisms control JAK-dependent signaling cascades. Like JAKs, epigenetic modifiers of the histone deacetylase (HDAC) family regulate the growth and development of cells and are often dysregulated in cancer cells. The notion that inhibitors of histone deacetylases (HDACi) abrogate oncogenic JAK-dependent signaling cascades illustrates an intricate crosstalk between JAKs and HDACs. Here, we summarize how structurally divergent, broad-acting as well as isoenzyme-specific HDACi, hybrid fusion pharmacophores containing JAKi and HDACi, and proteolysis targeting chimeras for JAKs inactivate the four JAK proteins JAK1, JAK2, JAK3, and tyrosine kinase-2. These agents suppress aberrant JAK activity through specific transcription-dependent processes and mechanisms that alter the phosphorylation and stability of JAKs. Pharmacological inhibition of HDACs abrogates allosteric activation of JAKs, overcomes limitations of ATP-competitive type 1 and type 2 JAKi, and interacts favorably with JAKi. Since such findings were collected in cultured cells, experimental animals, and cancer patients, we condense preclinical and translational relevance. We also discuss how future research on acetylation-dependent mechanisms that regulate JAKs might allow the rational design of improved treatments for cancer patients. SIGNIFICANCE STATEMENT: Reversible lysine-<b>ɛ</b>-N acetylation and deacetylation cycles control phosphorylation-dependent Janus kinase-signal transducer and activator of transcription signaling. The intricate crosstalk between these fundamental molecular mechanisms provides opportunities for pharmacological intervention strategies with modern small molecule inhibitors. This could help patients suffering from cancer.</p>","PeriodicalId":19780,"journal":{"name":"Pharmacological Reviews","volume":"75 1","pages":"35-61"},"PeriodicalIF":21.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9082584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins. G蛋白偶联受体与受体活性修饰蛋白相互作用的研究。
IF 21.1 1区 医学
Pharmacological Reviews Pub Date : 2023-01-01 Epub Date: 2022-12-08 DOI: 10.1124/pharmrev.120.000180
Ilana B Kotliar, Emily Lorenzen, Jochen M Schwenk, Debbie L Hay, Thomas P Sakmar
{"title":"Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins.","authors":"Ilana B Kotliar, Emily Lorenzen, Jochen M Schwenk, Debbie L Hay, Thomas P Sakmar","doi":"10.1124/pharmrev.120.000180","DOIUrl":"10.1124/pharmrev.120.000180","url":null,"abstract":"<p><p>G protein-coupled receptors (GPCRs) are known to interact with several other classes of integral membrane proteins that modulate their biology and pharmacology. However, the extent of these interactions and the mechanisms of their effects are not well understood. For example, one class of GPCR-interacting proteins, receptor activity-modifying proteins (RAMPs), comprise three related and ubiquitously expressed single-transmembrane span proteins. The RAMP family was discovered more than two decades ago, and since then GPCR-RAMP interactions and their functional consequences on receptor trafficking and ligand selectivity have been documented for several secretin (class B) GPCRs, most notably the calcitonin receptor-like receptor. Recent bioinformatics and multiplexed experimental studies suggest that GPCR-RAMP interactions might be much more widespread than previously anticipated. Recently, cryo-electron microscopy has provided high-resolution structures of GPCR-RAMP-ligand complexes, and drugs have been developed that target GPCR-RAMP complexes. In this review, we provide a summary of recent advances in techniques that allow the discovery of GPCR-RAMP interactions and their functional consequences and highlight prospects for future advances. We also provide an up-to-date list of reported GPCR-RAMP interactions based on a review of the current literature. SIGNIFICANCE STATEMENT: Receptor activity-modifying proteins (RAMPs) have emerged as modulators of many aspects of G protein-coupled receptor (GPCR)biology and pharmacology. The application of new methodologies to study membrane protein-protein interactions suggests that RAMPs interact with many more GPCRs than had been previously known. These findings, especially when combined with structural studies of membrane protein complexes, have significant implications for advancing GPCR-targeted drug discovery and the understanding of GPCR pharmacology, biology, and regulation.</p>","PeriodicalId":19780,"journal":{"name":"Pharmacological Reviews","volume":"75 1","pages":"1-34"},"PeriodicalIF":21.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/a7/pharmrev.120.000180.PMC9832379.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9449561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Dopamine, Immunity, and Disease. 多巴胺,免疫和疾病。
IF 21.1 1区 医学
Pharmacological Reviews Pub Date : 2023-01-01 DOI: 10.1124/pharmrev.122.000618
Breana Channer, Stephanie M Matt, Emily A Nickoloff-Bybel, Vasiliki Pappa, Yash Agarwal, Jason Wickman, Peter J Gaskill
{"title":"Dopamine, Immunity, and Disease.","authors":"Breana Channer,&nbsp;Stephanie M Matt,&nbsp;Emily A Nickoloff-Bybel,&nbsp;Vasiliki Pappa,&nbsp;Yash Agarwal,&nbsp;Jason Wickman,&nbsp;Peter J Gaskill","doi":"10.1124/pharmrev.122.000618","DOIUrl":"https://doi.org/10.1124/pharmrev.122.000618","url":null,"abstract":"<p><p>The neurotransmitter dopamine is a key factor in central nervous system (CNS) function, regulating many processes including reward, movement, and cognition. Dopamine also regulates critical functions in peripheral organs, such as blood pressure, renal activity, and intestinal motility. Beyond these functions, a growing body of evidence indicates that dopamine is an important immunoregulatory factor. Most types of immune cells express dopamine receptors and other dopaminergic proteins, and many immune cells take up, produce, store, and/or release dopamine, suggesting that dopaminergic immunomodulation is important for immune function. Targeting these pathways could be a promising avenue for the treatment of inflammation and disease, but despite increasing research in this area, data on the specific effects of dopamine on many immune cells and disease processes remain inconsistent and poorly understood. Therefore, this review integrates the current knowledge of the role of dopamine in immune cell function and inflammatory signaling across systems. We also discuss the current understanding of dopaminergic regulation of immune signaling in the CNS and peripheral tissues, highlighting the role of dopaminergic immunomodulation in diseases such as Parkinson's disease, several neuropsychiatric conditions, neurologic human immunodeficiency virus, inflammatory bowel disease, rheumatoid arthritis, and others. Careful consideration is given to the influence of experimental design on results, and we note a number of areas in need of further research. Overall, this review integrates our knowledge of dopaminergic immunology at the cellular, tissue, and disease level and prompts the development of therapeutics and strategies targeted toward ameliorating disease through dopaminergic regulation of immunity. SIGNIFICANCE STATEMENT: Canonically, dopamine is recognized as a neurotransmitter involved in the regulation of movement, cognition, and reward. However, dopamine also acts as an immune modulator in the central nervous system and periphery. This review comprehensively assesses the current knowledge of dopaminergic immunomodulation and the role of dopamine in disease pathogenesis at the cellular and tissue level. This will provide broad access to this information across fields, identify areas in need of further investigation, and drive the development of dopaminergic therapeutic strategies.</p>","PeriodicalId":19780,"journal":{"name":"Pharmacological Reviews","volume":"75 1","pages":"62-158"},"PeriodicalIF":21.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9440411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning. 心血管不可改变危险因素、合并症和并发症与缺血/再灌注损伤的相互作用以及药理学治疗和缺血条件下的心脏保护。
IF 19.3 1区 医学
Pharmacological Reviews Pub Date : 2023-01-01 Epub Date: 2022-12-08 DOI: 10.1124/pharmrev.121.000348
Péter Ferdinandy, Ioanna Andreadou, Gary F Baxter, Hans Erik Bøtker, Sean M Davidson, Dobromir Dobrev, Bernard J Gersh, Gerd Heusch, Sandrine Lecour, Marisol Ruiz-Meana, Coert J Zuurbier, Derek J Hausenloy, Rainer Schulz
{"title":"Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.","authors":"Péter Ferdinandy, Ioanna Andreadou, Gary F Baxter, Hans Erik Bøtker, Sean M Davidson, Dobromir Dobrev, Bernard J Gersh, Gerd Heusch, Sandrine Lecour, Marisol Ruiz-Meana, Coert J Zuurbier, Derek J Hausenloy, Rainer Schulz","doi":"10.1124/pharmrev.121.000348","DOIUrl":"10.1124/pharmrev.121.000348","url":null,"abstract":"<p><p>Preconditioning, postconditioning, and remote conditioning of the myocardium enhance the ability of the heart to withstand a prolonged ischemia/reperfusion insult and the potential to provide novel therapeutic paradigms for cardioprotection. While many signaling pathways leading to endogenous cardioprotection have been elucidated in experimental studies over the past 30 years, no cardioprotective drug is on the market yet for that indication. One likely major reason for this failure to translate cardioprotection into patient benefit is the lack of rigorous and systematic preclinical evaluation of promising cardioprotective therapies prior to their clinical evaluation, since ischemic heart disease in humans is a complex disorder caused by or associated with cardiovascular risk factors and comorbidities. These risk factors and comorbidities induce fundamental alterations in cellular signaling cascades that affect the development of ischemia/reperfusion injury and responses to cardioprotective interventions. Moreover, some of the medications used to treat these comorbidities may impact on cardioprotection by again modifying cellular signaling pathways. The aim of this article is to review the recent evidence that cardiovascular risk factors as well as comorbidities and their medications may modify the response to cardioprotective interventions. We emphasize the critical need for taking into account the presence of cardiovascular risk factors as well as comorbidities and their concomitant medications when designing preclinical studies for the identification and validation of cardioprotective drug targets and clinical studies. This will hopefully maximize the success rate of developing rational approaches to effective cardioprotective therapies for the majority of patients with multiple comorbidities. SIGNIFICANCE STATEMENT: Ischemic heart disease is a major cause of mortality; however, there are still no cardioprotective drugs on the market. Most studies on cardioprotection have been undertaken in animal models of ischemia/reperfusion in the absence of comorbidities; however, ischemic heart disease develops with other systemic disorders (e.g., hypertension, hyperlipidemia, diabetes, atherosclerosis). Here we focus on the preclinical and clinical evidence showing how these comorbidities and their routine medications affect ischemia/reperfusion injury and interfere with cardioprotective strategies.</p>","PeriodicalId":19780,"journal":{"name":"Pharmacological Reviews","volume":"75 1","pages":"159-216"},"PeriodicalIF":19.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/5c/pharmrev.121.000348.PMC9832381.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10347744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changing Cerebral Blood Flow, Glucose Metabolism, and Dopamine Binding Through Transcranial Magnetic Stimulation: A Systematic Review of Transcranial Magnetic Stimulation-Positron Emission Tomography Literature. 通过经颅磁刺激改变脑血流量、葡萄糖代谢和多巴胺结合:经颅磁激励正电子发射断层扫描文献的系统综述。
IF 21.1 1区 医学
Pharmacological Reviews Pub Date : 2022-10-01 DOI: 10.1124/pharmrev.122.000579
Kaitlin R Kinney, Colleen A Hanlon
{"title":"Changing Cerebral Blood Flow, Glucose Metabolism, and Dopamine Binding Through Transcranial Magnetic Stimulation: A Systematic Review of Transcranial Magnetic Stimulation-Positron Emission Tomography Literature.","authors":"Kaitlin R Kinney,&nbsp;Colleen A Hanlon","doi":"10.1124/pharmrev.122.000579","DOIUrl":"10.1124/pharmrev.122.000579","url":null,"abstract":"<p><p>Transcranial magnetic stimulation (TMS) is a noninvasive neuromodulation tool currently used as a treatment in multiple psychiatric and neurologic disorders. Despite its widespread use, we have an incomplete understanding of the way in which acute and chronic sessions of TMS affect various neural and vascular systems. This systematic review summarizes the state of our knowledge regarding the effects TMS may be having on cerebral blood flow, glucose metabolism, and neurotransmitter release. Forty-five studies were identified. Several key themes emerged: 1) TMS transiently increases cerebral blood flow in the area under the coil; 2) TMS to the prefrontal cortex increases glucose metabolism in the anterior cingulate cortex of patients with depression; and 3) TMS to the motor cortex and prefrontal cortex decreases dopamine receptor availability in the ipsilateral putamen and caudate respectively. There is, however, a paucity of literature regarding the effects TMS may have on other neurotransmitter and neuropeptide systems of interest, all of which may shed vital light on existing biologic mechanisms and future therapeutic development. SIGNIFICANCE STATEMENT: Transcranial magnetic stimulation (TMS) is a noninvasive neuromodulation tool currently used as a treatment in multiple psychiatric and neurologic disorders. This systematic review summarizes the state of our knowledge regarding the effects TMS on cerebral blood flow, glucose metabolism, and neurotransmitter release.</p>","PeriodicalId":19780,"journal":{"name":"Pharmacological Reviews","volume":"74 4","pages":"918-932"},"PeriodicalIF":21.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580100/pdf/pharmrev.122.000579.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9088488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Positive Allosteric Modulators of Glycine Receptors and Their Potential Use in Pain Therapies. 甘氨酸受体的正变构调节剂及其在疼痛治疗中的潜在应用。
IF 21.1 1区 医学
Pharmacological Reviews Pub Date : 2022-10-01 DOI: 10.1124/pharmrev.122.000583
Casey I Gallagher, Damien A Ha, Robert J Harvey, Robert J Vandenberg
{"title":"Positive Allosteric Modulators of Glycine Receptors and Their Potential Use in Pain Therapies.","authors":"Casey I Gallagher,&nbsp;Damien A Ha,&nbsp;Robert J Harvey,&nbsp;Robert J Vandenberg","doi":"10.1124/pharmrev.122.000583","DOIUrl":"10.1124/pharmrev.122.000583","url":null,"abstract":"<p><p>Glycine receptors are ligand-gated ion channels that mediate synaptic inhibition throughout the mammalian spinal cord, brainstem, and higher brain regions. They have recently emerged as promising targets for novel pain therapies due to their ability to produce antinociception by inhibiting nociceptive signals within the dorsal horn of the spinal cord. This has greatly enhanced the interest in developing positive allosteric modulators of glycine receptors. Several pharmaceutical companies and research facilities have attempted to identify new therapeutic leads by conducting large-scale screens of compound libraries, screening new derivatives from natural sources, or synthesizing novel compounds that mimic endogenous compounds with antinociceptive activity. Advances in structural techniques have also led to the publication of multiple high-resolution structures of the receptor, highlighting novel allosteric binding sites and providing additional information for previously identified binding sites. This has greatly enhanced our understanding of the functional properties of glycine receptors and expanded the structure activity relationships of novel pharmacophores. Despite this, glycine receptors are yet to be used as drug targets due to the difficulties in obtaining potent, selective modulators with favorable pharmacokinetic profiles that are devoid of side effects. This review presents a summary of the structural basis for how current compounds cause positive allosteric modulation of glycine receptors and discusses their therapeutic potential as analgesics. SIGNIFICANCE STATEMENT: Chronic pain is a major cause of disability, and in Western societies, this will only increase as the population ages. Despite the high level of prevalence and enormous socioeconomic burden incurred, treatment of chronic pain remains limited as it is often refractory to current analgesics, such as opioids. The National Institute for Drug Abuse has set finding effective, safe, nonaddictive strategies to manage chronic pain as their top priority. Positive allosteric modulators of glycine receptors may provide a therapeutic option.</p>","PeriodicalId":19780,"journal":{"name":"Pharmacological Reviews","volume":"74 4","pages":"933-961"},"PeriodicalIF":21.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553105/pdf/pharmrev.122.000583.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9080934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution. 迷幻自我消解的神经机制和心理学。
IF 21.1 1区 医学
Pharmacological Reviews Pub Date : 2022-10-01 DOI: 10.1124/pharmrev.121.000508
Devon Stoliker, Gary F Egan, Karl J Friston, Adeel Razi
{"title":"Neural Mechanisms and Psychology of Psychedelic Ego Dissolution.","authors":"Devon Stoliker,&nbsp;Gary F Egan,&nbsp;Karl J Friston,&nbsp;Adeel Razi","doi":"10.1124/pharmrev.121.000508","DOIUrl":"https://doi.org/10.1124/pharmrev.121.000508","url":null,"abstract":"<p><p>Neuroimaging studies of psychedelics have advanced our understanding of hierarchical brain organization and the mechanisms underlying their subjective and therapeutic effects. The primary mechanism of action of classic psychedelics is binding to serotonergic 5-HT2A receptors. Agonist activity at these receptors leads to neuromodulatory changes in synaptic efficacy that can have a profound effect on hierarchical message-passing in the brain. Here, we review the cognitive and neuroimaging evidence for the effects of psychedelics: in particular, their influence on selfhood and subject-object boundaries-known as ego <i>dissolution</i>-surmised to underwrite their subjective and therapeutic effects. Agonism of 5-HT2A receptors, located at the apex of the cortical hierarchy, may have a particularly powerful effect on sentience and consciousness. These effects can endure well after the pharmacological half-life, suggesting that psychedelics may have effects on neural plasticity that may play a role in their therapeutic efficacy. Psychologically, this may be accompanied by a disarming of ego <i>resistance</i> that increases the repertoire of perceptual hypotheses and affords alternate pathways for thought and behavior, including those that undergird selfhood. We consider the interaction between serotonergic neuromodulation and sentience through the lens of hierarchical predictive coding, which speaks to the value of psychedelics in understanding how we make sense of the world and specific predictions about effective connectivity in cortical hierarchies that can be tested using functional neuroimaging. SIGNIFICANCE STATEMENT: Classic psychedelics bind to serotonergic 5-HT2A receptors. Their agonist activity at these receptors leads to neuromodulatory changes in synaptic efficacy, resulting in a profound effect on information processing in the brain. Here, we synthesize an abundance of brain imaging research with pharmacological and psychological interpretations informed by the framework of predictive coding. Moreover, predictive coding is suggested to offer more sophisticated interpretations of neuroimaging findings by bridging the role between the 5-HT2A receptors and large-scale brain networks.</p>","PeriodicalId":19780,"journal":{"name":"Pharmacological Reviews","volume":"74 4","pages":"876-917"},"PeriodicalIF":21.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9166267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring Intestinal Surface Receptors in Oral Nanoinsulin Delivery. 探索肠道表面受体在口服纳米胰岛素递送中的作用。
IF 21.1 1区 医学
Pharmacological Reviews Pub Date : 2022-10-01 DOI: 10.1124/pharmrev.122.000631
Carlynne Choy, Lee Yong Lim, Lai Wah Chan, Zhixiang Cui, Shirui Mao, Tin Wui Wong
{"title":"Exploring Intestinal Surface Receptors in Oral Nanoinsulin Delivery.","authors":"Carlynne Choy,&nbsp;Lee Yong Lim,&nbsp;Lai Wah Chan,&nbsp;Zhixiang Cui,&nbsp;Shirui Mao,&nbsp;Tin Wui Wong","doi":"10.1124/pharmrev.122.000631","DOIUrl":"https://doi.org/10.1124/pharmrev.122.000631","url":null,"abstract":"<p><p>Subcutaneous and inhaled insulins are associated with needle phobia, lipohypertrophy, lipodystrophy, and cough in diabetes treatment. Oral nanoinsulin has been developed, reaping the physiologic benefits of peroral administration. This review profiles intestinal receptors exploitable in targeted delivery of oral nanoinsulin. Intestinal receptor targeting improves oral insulin bioavailability and sustains blood glucose-lowering response. Nonetheless, these studies are conducted in small animal models with no optimization of insulin dose, targeting ligand type and content, and physicochemical and molecular biologic characteristics of nanoparticles against the in vivo/clinical diabetes responses as a function of the intestinal receptor population characteristics with diabetes progression. The interactive effects between nanoinsulin and antidiabetic drugs on intestinal receptors, including their up-/downregulation, are uncertain. Sweet taste receptors upregulate SGLT-1, and both have an undefined role as new intestinal targets of nanoinsulin. Receptor targeting of oral nanoinsulin represents a viable approach that is relatively green, requiring an in-depth development of the relationship between receptors and their pathophysiological profiles with physicochemical attributes of the oral nanoinsulin. SIGNIFICANCE STATEMENT: Intestinal receptor targeting of oral nanoinsulin improves its bioavailability with sustained blood glucose-lowering response. Exploring new intestinal receptor and tailoring the design of oral nanoinsulin to the pathophysiological state of diabetic patients is imperative to raise the insulin performance to a comparable level as the injection products.</p>","PeriodicalId":19780,"journal":{"name":"Pharmacological Reviews","volume":"74 4","pages":"962-983"},"PeriodicalIF":21.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9088490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological Reviews Announces Inaugural Social Media Ambassadors 药理学评论宣布就任社交媒体大使
IF 21.1 1区 医学
Pharmacological Reviews Pub Date : 2022-09-30 DOI: 10.1124/pharmrev.122.000697
L. Daws
{"title":"Pharmacological Reviews Announces Inaugural Social Media Ambassadors","authors":"L. Daws","doi":"10.1124/pharmrev.122.000697","DOIUrl":"https://doi.org/10.1124/pharmrev.122.000697","url":null,"abstract":"","PeriodicalId":19780,"journal":{"name":"Pharmacological Reviews","volume":"74 1","pages":"1206 - 1206"},"PeriodicalIF":21.1,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45089201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics. 质谱法增强了神经肽的发现和治疗。
IF 21.1 1区 医学
Pharmacological Reviews Pub Date : 2022-07-01 DOI: 10.1124/pharmrev.121.000423
Krishna D B Anapindi, Elena V Romanova, James W Checco, Jonathan V Sweedler
{"title":"Mass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics.","authors":"Krishna D B Anapindi,&nbsp;Elena V Romanova,&nbsp;James W Checco,&nbsp;Jonathan V Sweedler","doi":"10.1124/pharmrev.121.000423","DOIUrl":"https://doi.org/10.1124/pharmrev.121.000423","url":null,"abstract":"<p><p>The discovery of insulin in the early 1900s ushered in the era of research related to peptides acting as hormones and neuromodulators, among other regulatory roles. These essential gene products are found in all organisms, from the most primitive to the most evolved, and carry important biologic information that coordinates complex physiology and behavior; their misregulation has been implicated in a variety of diseases. The evolutionary origins of at least 30 neuropeptide signaling systems have been traced to the common ancestor of protostomes and deuterostomes. With the use of relevant animal models and modern technologies, we can gain mechanistic insight into orthologous and paralogous endogenous peptides and translate that knowledge into medically relevant insights and new treatments. Groundbreaking advances in medicine and basic science influence how signaling peptides are defined today. The precise mechanistic pathways for over 100 endogenous peptides in mammals are now known and have laid the foundation for multiple drug development pipelines. Peptide biologics have become valuable drugs due to their unique specificity and biologic activity, lack of toxic metabolites, and minimal undesirable interactions. This review outlines modern technologies that enable neuropeptide discovery and characterization, and highlights lessons from nature made possible by neuropeptide research in relevant animal models that is being adopted by the pharmaceutical industry. We conclude with a brief overview of approaches/strategies for effective development of peptides as drugs. SIGNIFICANCE STATEMENT: Neuropeptides, an important class of cell-cell signaling molecules, are involved in maintaining a range of physiological functions. Since the discovery of insulin's activity, over 100 bioactive peptides and peptide analogs have been used as therapeutics. Because these are complex molecules not easily predicted from a genome and their activity can change with subtle chemical modifications, mass spectrometry (MS) has significantly empowered peptide discovery and characterization. This review highlights contributions of MS-based research towards the development of therapeutic peptides.</p>","PeriodicalId":19780,"journal":{"name":"Pharmacological Reviews","volume":"74 3","pages":"662-679"},"PeriodicalIF":21.1,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553102/pdf/pharmrev.121.000423.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9731405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信